Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197264
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bastard, Paul | - |
dc.contributor.author | Rocamora Blanch, Gemma | - |
dc.contributor.author | Pujol Onofre, Aurora | - |
dc.contributor.author | Martínez Picado, Francisco Javier | - |
dc.contributor.author | Solanich, Xavier | - |
dc.contributor.author | Anderson, Mark S. | - |
dc.contributor.author | Casanova, Jean Laurent | - |
dc.contributor.author | Derisi, Joseph L. | - |
dc.contributor.author | Antolí, Arnau | - |
dc.date.accessioned | 2023-04-26T13:43:19Z | - |
dc.date.available | 2023-04-26T13:43:19Z | - |
dc.date.issued | 2022-06-14 | - |
dc.identifier.issn | 2470-9468 | - |
dc.identifier.uri | http://hdl.handle.net/2445/197264 | - |
dc.description.abstract | Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population. | - |
dc.format.extent | 18 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Science Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1126/sciimmunol.abp8966 | - |
dc.relation.ispartof | Science Immunology, 2022 | - |
dc.relation.uri | https://doi.org/10.1126/sciimmunol.abp8966 | - |
dc.rights | cc by (c) Bastard, Paul et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Pneumònia | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Pneumonia | - |
dc.title | Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-04-13T15:08:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35857576 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sciimmunol.abp8966.pdf | 671.7 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License